stockrow
Monday 9 November 2026
Export ELDN’s income statement to Excel — free account
Eledon Pharmaceuticals, Inc.
ELDN- EPS
- −107.7%
- Free cash flow
- −28.0%
Quarter to June 2026, against a year earlier
2.61
0.15
+6.10%
Follow ELDN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (6) | (13) | (14) | (16) | (23) | (37) | (88) | (117) | (36) | (46) | (99) | +26.1% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (6) | (13) | (14) | (16) | (23) | (35) | (88) | (117) | (36) | (46) | (99) | +26.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (271.43) | (41.37) | (28.06) | (24.46) | (15.72) | (2.33) | (6.16) | (4.73) | (0.75) | (0.52) | (0.91) | (50.1%) | ||||||
| Cash flow | (231.13) | (57.44) | (23.75) | (21.12) | (10.48) | (1.95) | (1.99) | (1.61) | (0.97) | (0.76) | (0.65) | (47.0%) | ||||||
| Capex | 0.05 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (231.08) | (57.41) | (23.75) | (21.12) | (10.48) | (1.95) | (1.99) | (1.61) | (0.97) | (0.76) | (0.65) | (47.0%) | ||||||
| Book value | (126.85) | 74.79 | 28.94 | 14.43 | 131.35 | 11.07 | 5.89 | 0.29 | 2.43 | 1.67 | 0.63 | n/m | ||||||
| Shares, m | 0 | 0 | 1 | 1 | 1 | 15 | 14 | 25 | 49 | 82 | 96 | +150.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (5) | (15) | (12) | (14) | (15) | (29) | (28) | (40) | (47) | (62) | (74) | +32.6% | |||||
| Capex | 0 | 0 | — | — | — | — | — | — | — | — | 0 | +700.0% | ||||||
| Free cash flow | (5) | (15) | (12) | (14) | (15) | (29) | (28) | (40) | (47) | (62) | (74) | +32.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | (3) | 18 | 12 | 9 | 113 | 84 | 53 | 52 | 132 | 117 | 81 | n/m | |||||
| Net debt | 2 | (17) | (13) | (9) | (114) | (85) | (56) | (51) | (140) | (133) | (89) | n/m | ||||||
| Shareholders’ equity | (3) | 19 | 14 | 9 | 191 | 164 | 84 | 7 | 118 | 137 | 72 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (16.35) | (97.59) | (74.19) | (114.54) | (21.92) | (18.77) | (66.81) | (128.16) | (27.16) | (26.34) | (72.74) | (10.0) pt | |||||
| ROIC | 0.00 | (381.60) | (578.13) | (1,488.41) | (15.11) | (29.11) | (198.99) | 0.00 | 0.00 | (1,511.24) | 0.00 | (1,511.2) pt | ||||||
| ROE | (19.17) | (128.84) | (82.87) | (133.66) | (22.80) | (19.46) | (70.89) | (652.92) | (518.40) | (63.56) | (236.51) | (44.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 8 | 7 | 10 | 8 | 10 | 12 | 17 | 20 | 31 | 33 | — | +17.1% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Eledon Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SLGL Sol-Gel Technologies Ltd. | $206.3M | — (loss-making) | — (loss-making) | −96.58% (below 0%: shrinking) | n/m | −8.76% (below 0%: shrinking) | 100.00% | (704.23%) | Compare |
| RNAC Cartesian Therapeutics, Inc. | $205.1M | — (loss-making) | — (loss-making) | −92.91% (below 0%: shrinking) | −7.84% (below 0%: shrinking) | −6.15% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| DRUG Bright Minds Biosciences Inc. | $204.2M | — (loss-making) | — | — | n/m | −124.63% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PLX Protalix BioTherapeutics, Inc. | $202.2M | 10.5× | 10.6× | +27.07% (above 0%: growing) | +2,280.95% (above 0%: growing) | −94.09% (below 0%: shrinking) | 60.99% | 23.48% | Compare |
| PALI Palisade Bio, Inc. | $202.2M | 1.8× | — (loss-making) | +19,900.00% (above 0%: growing) | n/m | −318.44% (below 0%: shrinking) | 100.00% | (2,339.60%) | Compare |
| ARTV Artiva Biotherapeutics, Inc. | $201.9M | — (loss-making) | — (loss-making) | — | n/m | +13.60% (above 0%: growing) | 100.00% | 0.00% | Compare |
| IKT Inhibikase Therapeutics, Inc. | $200.9M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −123.23% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ELDN Eledon Pharmaceuticals, Inc. | $199.9M | — (loss-making) | — | — | n/m | −28.02% (below 0%: shrinking) | 0.00% | 0.00% | |
| IFRX InflaRx N.V. | $199.7M | — (loss-making) | — (loss-making) | −128.93% (below 0%: shrinking) | n/m | +59.76% (above 0%: growing) | 14,029.95% | 0.00% | Compare |
| Median of peers | $202.2M | — | — | −94.74% | — | −51.42% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 30 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 3.22m | (315.00k) | 66.23 |
| 2024 | 5.64m | 6.79m | 180.70 |
| 2023 | 2.55m | 404.58k | 78.95 |
Ownership
Directors and executive officers, together
9.60%
Entities affiliated with BVF Partners L.P.
8.30%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement